$1.53
-0.01 (-0.65%)
Performance
1D
—
1W
—
1M
—
3M
-13.07%
6M
-72.48%
1Y
-63.04%
YTD
-63.04%
Open$1.55
Previous Close$1.54
Day High$1.55
Day Low$1.49
52W High$6.18
52W Low$1.07
Volume—
Avg Volume830.9K
Market Cap95.91M
P/E Ratio—
EPS$-0.46
SectorBiotechnology
Technical Indicators
Full analysis →
SMA 50
$1.68
Below
RSI (14)
47.8
Neutral
Analyst Ratings
Strong Buy
12 analysts
Price Target
+2,722.2% upside
Current
$1.53
$1.53
Target
$43.18
$43.18
$31.72
$43.18 avg
$59.84
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 34.78M | 32.14M | 39.05M |
| Net Income | 5.77M | 7.01M | 8.10M |
| Profit Margin | 16.6% | 21.8% | 20.7% |
| EBITDA | 11.08M | 11.55M | 13.91M |
| Free Cash Flow | 4.11M | 3.56M | 7.02M |
| Rev Growth | +3.0% | +6.5% | +17.8% |
| Debt/Equity | 0.16 | 0.15 | 0.16 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |